Keywords: fda, approves, atrix, prostate, cancer, depot, laboratories
FDA approves Atrix' prostate cancer depot
Article | 28 January 2002
Atrix Laboratories has been granted approval by the US Food and DrugAdministration for Eligard (leuprolide acetate 7.5mg), its subcutaneous one-month ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
